 Tuberculosis, Multidrug-Resistant
"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Descriptor ID |
D018088
|
| MeSH Number(s) |
C01.252.410.040.552.846.775
|
| Concept/Terms |
Tuberculosis, Multidrug-Resistant- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
|
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in UAMS Profiles by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 1 | 0 | 1 | | 2022 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2017 | 4 | 0 | 4 | | 2016 | 6 | 0 | 6 | | 2015 | 4 | 1 | 5 | | 2014 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2012 | 1 | 1 | 2 | | 2011 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles over the past ten years.
-
Syed RR, Catanzaro DG, Colman RE, Cooney CG, Linger Y, Kukhtin AV, Holmberg RC, Norville R, Crudu V, Ciobanu N, Codreanu A, Seifert M, Hillery N, Chiles P, Catanzaro A, Rodwell TC. Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. J Clin Microbiol. 2023 03 23; 61(3):e0147822.
-
Smith-Jeffcoat SE, Eisenach KD, Joloba M, Ssengooba W, Namaganda C, Nsereko M, Okware B, Cavanaugh JS, Cegielski JP. Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment. Int J Tuberc Lung Dis. 2022 Nov 01; 26(11):1058-1064.
-
Demers AM, Kim S, McCallum S, Eisenach K, Hughes M, Naini L, Mendoza-Ticona A, Pradhan N, Narunsky K, Poongulali S, Badal-Faesen S, Upton C, Smith E, Shah NS, Churchyard G, Gupta A, Hesseling A, Swindells S. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial. BMC Infect Dis. 2021 Feb 24; 21(1):205.
-
Catanzaro DG, Colman RE, Linger Y, Georghiou SB, Kukhtin AV, Seifert M, Holmberg RC, Mshaiel H, Chiles P, Hillery N, Cooney CG, Rodwell TC. Laboratory Evaluation of a Lateral-Flow Cell for Molecular Detection of First-Line and Second-Line Antituberculosis Drug Resistance. J Clin Microbiol. 2020 10 21; 58(11).
-
Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, Lemmer D, Engelthaler DM, Catanzaro DG, Young AG, Denkinger CM, Rodwell TC. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med. 2019 04; 16(4):e1002794.
-
Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrob Agents Chemother. 2018 10; 62(10).
-
Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017 Nov 25; 18(1):563.
-
Seifert M, Georghiou SB, Garfein RS, Catanzaro D, Rodwell TC. Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis. Clin Infect Dis. 2017 Sep 01; 65(5):772-778.
-
Georghiou SB, Seifert M, Catanzaro DG, Garfein RS, Rodwell TC. Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs. J Clin Microbiol. 2017 06; 55(6):1928-1937.
-
Catanzaro DG, Trollip AP, Seifert M, Georghiou SB, Garfein RS, Rodwell TC, Catanzaro A, Eisenach KD. Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis. Eur Respir J. 2017 04; 49(4).
-
Conners E, Garfein RS, Rodwell TC, Udwadia ZF, Catanzaro DG. Mobility patterns of persons at risk for drug-resistant tuberculosis in Mumbai, India. Int J Tuberc Lung Dis. 2016 12; 20(12):1633-1638.
-
Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC. Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother. 2016 07; 60(7):3994-4004.
-
Seifert M, Ajbani K, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC. A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 May; 20(5):631-7.
-
Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 2016 Mar; 20(3):290-4.
-
Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC. MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis. J Clin Microbiol. 2016 Apr; 54(4):912-8.
-
Dom?nguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, Hillemann D, Horsburgh R, Molina-Moya B, Niemann S, Tortoli E, Whitelaw A, Lange C. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis. 2016 Jan; 20(1):24-42.
-
Yamada S, Riklon S, Maskarinec GG. Ethical Responsibility for the Social Production of Tuberculosis. J Bioeth Inq. 2016 Mar; 13(1):57-64.
-
Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert M, Georghiou SB, Trollip A, Groessl E, Hillery N, Crudu V, Victor TC, Rodrigues C, Lin GS, Valafar F, Desmond E, Eisenach K. Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis. PLoS One. 2015; 10(8):e0136861.
-
Colman RE, Schupp JM, Hicks ND, Smith DE, Buchhagen JL, Valafar F, Crudu V, Romancenco E, Noroc E, Jackson L, Catanzaro DG, Rodwell TC, Catanzaro A, Keim P, Engelthaler DM. Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing. PLoS One. 2015; 10(5):e0126626.
-
Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015; 10(3):e0119628.
-
Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|